Irbesartan in Heart Failure With Preserved Ejection Fraction Study - I-PRESERVE

Description:

Patients with symptomatic heart failure (HF) and normal to near-normal ejection fraction (EF) have different pathophysiological alterations compared with those with HF and low EF, and current therapies for this condition are limited. Basic science studies have demonstrated that plasma renin activity is enhanced in patients with HF and normal EF. Accordingly, the I-PRESERVE study sought to evaluate the effect of angiotensin-receptor blockade with irbesartan on cardiovascular outcomes in these ...